May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Subconjunctival Injection(s) of Bevacizumab for Failing Filtering Blebs
Author Affiliations & Notes
  • F. M. Kapetansky
    Ophthalmology, Ohio State University, Columbus, Ohio
  • K. S. Pappa
    Ophthalmology, Ohio State University, Columbus, Ohio
  • M. A. Krasnow
    Family Practice & Ophthalmology, Marshall University, Huntington, West Virginia
  • N. D. Baker
    Ophthalmology, Ohio State University, Columbus, Ohio
  • C. D. Francis
    Family Practice & Ophthalmology, Marshall University, Huntington, West Virginia
  • Footnotes
    Commercial Relationships  F.M. Kapetansky, None; K.S. Pappa, None; M.A. Krasnow, None; N.D. Baker, None; C.D. Francis, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4149. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. M. Kapetansky, K. S. Pappa, M. A. Krasnow, N. D. Baker, C. D. Francis; Subconjunctival Injection(s) of Bevacizumab for Failing Filtering Blebs. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4149. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Proliferation of Tenon's capsule fibroblasts and increased vascularization of the conjunctiva represent major threats to the survival of a glaucoma filtering bleb. Wong, et al studied angiogenesis inhibition of Tenon's capsule fibroblasts. Kahook, et al reported a single case of angiogenesis inhibition with bevacizumab following needle revision of a bleb. Jain, et al studied the characteristics of the bleb following subconjunctival bevacizumab vs topical mitomycin-c. This prospective, non-randomized, open label study is an extension of our previously reported results of the effect of subconjunctival injection of bevacizumab (Avastin) on vascularization of a filtering bleb.

Methods: : 39 eyes with primary open angle glaucoma (POAG), normal tension glaucoma (NTG), or exfoliation syndrome (PXE) had a trabeculectomy, augmented with mitomycin or 5-FU, between November 1997 and October 2006. A subconjunctival injection of Avastin (1.0 mg) was administered proximal to the bleb at the earliest sign of vascularization. If there was still excessive vascularity of the bleb, then the injection was repeated. The intraocular pressure (IOP), bleb vascularity, and fibrosis were evaluated weekly until there was stability. Re-evaluations were done monthly for the first 6 months, and then every 3 months for a maximum of 18 months.

Results: : 31 eyes had a diagnosis of POAG, 5 eyes NTG, and 4 eyes PXE. Mean age was 72 years (range 44-87). Cohort was 34 Caucasians, 4 African-Americans, and 1 Asian. The mean pre-injection IOP was 17.8 mm Hg + 6.4. One month post-injection, the IOP was 14 mm Hg + 4.5. By the Wilcoxon signed ranks test, this decrease in IOP was statistically significant (p=0.001). Injections early in the postoperative period yielded the most stable IOP. The probability of failure was related to delaying the postoperative injection. There was no evidence of an untoward reaction from the injection of Avastin.

Conclusions: : In this pilot study, 39 eyes with open angle glaucoma (POAG, NTG, PXE) received subconjunctival injections of Avastin (1 mg) following trabeculectomy. All IOP measurements after the Avastin injection were equal to or less than their corresponding pre-injection IOP. The one month post-injection IOP was statistically significant (p=0.001). Follow-up was up to 18 months. Nearly 2/3 of these eyes had an observable reduction in vascularity of the filtering bleb. There were no complications traceable to the Avastin injection.

Keywords: wound healing • conjunctiva • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×